191 related articles for article (PubMed ID: 22454061)
1. Optimizing splice-switching oligomer sequences using 2'-O-methyl phosphorothioate chemistry.
Adkin C; Fletcher S; Wilton SD
Methods Mol Biol; 2012; 867():169-88. PubMed ID: 22454061
[TBL] [Abstract][Full Text] [Related]
2. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
Takeshima Y; Yagi M; Matsuo M
Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
4. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
5. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
7. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
8. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
9. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
10. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
11. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
[TBL] [Abstract][Full Text] [Related]
12. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
13. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
[TBL] [Abstract][Full Text] [Related]
14. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
15. Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching.
Fragall CT; Adams AM; Johnsen RD; Kole R; Fletcher S; Wilton SD
BMC Med Genet; 2011 Oct; 12():141. PubMed ID: 22013876
[TBL] [Abstract][Full Text] [Related]
16. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
18. Splicing intervention for Duchenne muscular dystrophy.
McClorey G; Fletcher S; Wilton S
Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
[TBL] [Abstract][Full Text] [Related]
19. Exon skipping quantification by real-time PCR.
Ferlini A; Rimessi P
Methods Mol Biol; 2012; 867():189-99. PubMed ID: 22454062
[TBL] [Abstract][Full Text] [Related]
20. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
